EU Orphan Drug Designation is approved for PB-04 for treatment of Sickle Cell Disease

December 14, 2018  Phoenicia BioSciences has received notice of approval of  their application for Orphan Drug Designation for product PB-04 in the European Union. Orphan Drug Designation allows 12 years of market exclusivity following marketing approval for a new drug for treatment of adult and pediatric orphan populations.

Phoenicia BioSciences’  CMO Dr. Susan Perrine has received notice that a 20th US Patent, Number 10,111,846 B2 was approved  on October 30, 2018 for a therapeutic candidate designated ST7S, a small molecule which dramatically stimulates white blood cell proliferation and other blood cell lineages following radiation and has prolonged survival in radiated mice, in studies by AFFRI, the Armed Forces Radiobiology Research Institute.